Sponsor hub

Wake Forest University Health Sciences clinical trial failures

Review 130 stopped clinical trials from Wake Forest University Health Sciences, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 6 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials130
Likely biological signals6
Shown below100

Dominant stop reasons

OPERATIONAL
88
OTHER/UNKNOWN
36
SAFETY
4
EFFICACY/FUTILITY
2

Notable sponsors

Wake Forest University Health Sciences
130

Related phases

Phase II
59
Phase IV
23
Phase I
19
Early Phase I
14
Unknown
10

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT05601492: Adherence to Otezla

Early Phase I Psoriasis trial by Wake Forest University Health Sciences. Stop reason: OPERATIONAL.

Terminated IRB approval 6/26/2024, study was never initiated or activated

NCT03979664: Iontophoresis in Psoriasis

Early Phase I Psoriasis trial by Wake Forest University Health Sciences. Stop reason: OTHER/UNKNOWN.

FDA did not provide approval of the use of the drug for the study